A study concludes that fake ISO 9001 quality certificates are very widespread across Chinese companies and that the certification processes of the auditing companies lack credibility.

Methyl groups of neurons derived from mouse fibroblast cells match those from naturally developed cells, providing further validation of these cells as a suitable model for research.

An FDA-approved drug has been identified that, when used with surgery, hampers metastasis in an animal model. Originally developed and approved ~65 years ago to control blood pressure, the medication resperine also prevents what are known as tumor-derived extracellular vesicles from fusing to healthy cells and sharing their cargo of disease-promoting molecules.

Looking at the industry growth and the complexities of biopharma development, it is no wonder that transformational developments are required to better equip laboratories and operations in biopharma.

This article discusses the relationship between cell signaling and cancer, highlights key signaling pathways involved in cancer, and explores how critical mediators of aberrant signaling can be turned into therapeutic targets for cancer.

High-throughput single-cell analysis has been regularly acclaimed as a transformative technology for sequencing and a huge step towards the goal of personalized medicine. Will Tapestri, a sequencing platform developed by Mission Bio, be the game-changer in DNA analysis we have been waiting for?

A Chinese scientist, He Jiankui, has claimed that he helped make the world-first gene-edited babies: two twin baby girls. Reportedly, he used CRISPR-Cas9 to edit embryos for seven couples during IVF fertility treatment, and engineered the embryos to possess resistance to HIV infection. He Jiankui, from the Southern University of Science and Technology, is now facing investigation over whether the experiment was illegal.

CRISPR-based gene editing has been implemented across the scientific community in the past 5 years. Although CRISPR is relatively easy and efficient compared to previous gene editing methods, researchers are continuing to improve the technology. New advancements are designed to make different types of genetic changes, improve efficiency, and improve delivery of CRISPR for different therapeutic approaches.

Although many new cellular assays entered the drug discovery scene over the course of the last decades, we still lack a predictable tool when it comes to selecting compounds or cell lines for xenograft testing. What is lacking?